Similar articles for PMID: 28572289

Year	Number of Results
1965	1
1988	1
1990	1
2000	1
2002	2
2003	4
2004	3
2005	4
2006	3
2007	6
2008	12
2009	8
2010	8
2011	10
2012	14
2013	12
2014	16
2015	8
2016	24
2017	20
2018	19
2019	12
2020	13
2021	13
2022	9
2023	5
2024	0

1

Parametric Method Performance for Dynamic 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.

Kramer GM, Frings V, Heijtel D, Smit EF, Hoekstra OS, Boellaard R; QuIC-ConCePT Consortium. Kramer GM, et al. J Nucl Med. 2017 Jun;58(6):920-925. doi: 10.2967/jnumed.116.178418. Epub 2016 Nov 10. J Nucl Med. 2017. PMID: 28572289 Free article. Clinical Trial.

2

Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.

Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, Cachin F, Berriolo-Riedinger A, Olivier P, Kolesnikov-Gauthier H, Blagosklonov O, Bridji B, Devillers A, Collombier L, Courbon F, Gremillet E, Houzard C, Caignon JM, Roux J, Aide N, Brenot-Rossi I, Doyeux K, Dubray B, Vera P. Thureau S, et al. J Nucl Med. 2013 Sep;54(9):1543-50. doi: 10.2967/jnumed.112.118083. Epub 2013 Aug 5. J Nucl Med. 2013. PMID: 23918733 Free article. Clinical Trial.

3

Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.

Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, Wells JM, Krohn KA. Muzi M, et al. J Nucl Med. 2005 Feb;46(2):274-82. J Nucl Med. 2005. PMID: 15695787 Free article. Clinical Trial.

4

Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.

Frings V, Yaqub M, Hoyng LL, Golla SS, Windhorst AD, Schuit RC, Lammertsma AA, Hoekstra OS, Smit EF, Boellaard R; QuIC-ConCePT Consortium. Frings V, et al. J Nucl Med. 2014 Sep;55(9):1417-23. doi: 10.2967/jnumed.114.140913. Epub 2014 Jun 26. J Nucl Med. 2014. PMID: 24970910 Free article.

5

3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.

Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S. Zannetti A, et al. J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13. J Nucl Med. 2012. PMID: 22331221 Free article.

6

Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.

Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, Boellaard R. Kramer GM, et al. J Nucl Med. 2016 Sep;57(9):1343-9. doi: 10.2967/jnumed.115.170225. Epub 2016 Apr 21. J Nucl Med. 2016. PMID: 27103020 Free article.

7

Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.

Tixier F, Vriens D, Cheze-Le Rest C, Hatt M, Disselhorst JA, Oyen WJ, de Geus-Oei LF, Visser EP, Visvikis D. Tixier F, et al. J Nucl Med. 2016 Jul;57(7):1033-9. doi: 10.2967/jnumed.115.166918. Epub 2016 Mar 10. J Nucl Med. 2016. PMID: 26966161 Free article.

8

Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients.

Verwer EE, Bahce I, van Velden FH, Yaqub M, Schuit RC, Windhorst AD, Raijmakers P, Hoekstra OS, Lammertsma AA, Smit EF, Boellaard R. Verwer EE, et al. J Nucl Med. 2014 Nov;55(11):1772-7. doi: 10.2967/jnumed.114.141846. Epub 2014 Oct 16. J Nucl Med. 2014. PMID: 25324522 Free article.

9

Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.

Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, Boellaard R. Frings V, et al. J Nucl Med. 2010 Dec;51(12):1870-7. doi: 10.2967/jnumed.110.077255. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078791 Free article.

10

Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.

Bhoil A, Singh B, Singh N, Kashyap R, Watts A, Sarika S, Mittal BR. Bhoil A, et al. Hell J Nucl Med. 2014 May-Aug;17(2):90-6. doi: 10.1967/s002449910136. Epub 2014 Jul 5. Hell J Nucl Med. 2014. PMID: 24997081 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

197 results

Results by year